News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Capital return
Novo Nordisk A/S Bagsværd, Denmark, 17 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly …
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead …
Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …
Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …
Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …
Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …
In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution …
Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower …
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the drugmaker behind Zepbound, won a legal victory alongside Novo Nordisk after a federal judge dismissed an antitrust lawsuit over access to compounded GLP-1 drugs. Warning! GuruFocus has detected 5 Warning Signs …
This article first appeared on GuruFocus. Total Revenue: $0.7 million for Q2 2026, compared to $28.9 million in Q2 2025. Licensing Revenue: Q2 2025 included $27.5 million in licensing revenue from the Novo Nordisk agreement; no comparable revenue was recognized in Q2 2026. R&D …
Novo Nordisk A/S NVO used its second-quarter 2026 earnings call to emphasize stronger GLP-1 momentum, led by Wegovy pill, while highlighting pricing pressure, patent expirations and competition. The company raised its full-year outlook after adjusted sales and operating profit grew 7% and 11%, respectively, …
In 2023, Danish drugmaker Novo Nordisk briefly surpassed the luxury conglomerate LVMH to become Europe's most valuable company by market capitalization. Its share price was propelled upwards by soaring sales of its breakthrough weight-loss drugs Ozempic and Wegovy. After pioneering GLP-1 treatments to combat …
Lexicon Pharmaceuticals, Inc. Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET …
Novo Nordisk A/S Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market …
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Wegovy and Ozempic, raised its full-year outlook on Wednesday, but that still wasn't enough to satisfy investors. The stock slid more than 4% in Copenhagen trading as Wall Street looked …
The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes. Continue Reading
Novo Nordisk A/S NVO reported adjusted second-quarter 2026 earnings of 96 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 82 cents. The company had reported adjusted earnings of 90 cents per ADR in the year-ago quarter. Revenues of $12.21 …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the …
Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back PREMIUM Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to …
Global scientific informatics leaders outline how the industry must conquer scientific data today to prepare for tomorrow. BASEL, Switzerland, Aug. 5, 2026 /PRNewswire/ -- Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Basel convened leading experts from companies such as Roche, Bayer, Novo Nordisk, …
Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) raised its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated. But shares fell 6% in U.S. trading Tuesday after the company's new Wegovy pill …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk has reported headline phase 3 results from the ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The study …
Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early. Continue Reading
The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes. Continue Reading
Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early. Continue Reading
Novo Nordisk A/S Bagsværd, 4 August 2026 - Financial report for the period 1 January 2026 to 30 June 2026 Financial performance Q2 2026 reported sales increased by 3% at CER, with growth negatively impacted by a DKK 2.6 billion rebate provision reversal related …
H1 Partnership builds on Novo Nordisk's AI and digital foundation to enhance clinical trial design and execution through AI-enabled workflows and insights H1 Partners with Novo Nordisk to Scale AI-Driven Clinical DevelopmentAriel Katz, CEO of H1 NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- …
One year since becoming Novo Nordisk’s chief executive, Mike Doustdar is betting on the “phenomenal” sales of its weight-loss pill, new PREMIUM Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access …
Novo Nordisk NVO is scheduled to report its second-quarter 2026 results on Aug. 5, 2026, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.27 billion, while the same for earnings is pinned at 82 …
Search by ticker symbol or company name and select a result to open its chart.